{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:53:22Z","timestamp":1781312002491,"version":"3.54.1"},"reference-count":18,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,6,1]]},"abstract":"<jats:p>Atypical hemolytic uremic syndrome (aHUS) is a life-threatening multisystemic condition often leading to end-stage renal failure. It results from an increased activation of the alternative pathway of the complement system due to mutations of genes coding for inhibitors of this pathway or from autoantibodies directed against them. Eculizumab is a monoclonal antibody directed against complement component C5 and inhibiting the activation of the effector limb of the complement system. Its efficacy has already been demonstrated in aHUS. The present article reports for the first time the use of eculizumab in a patient presenting with aHUS associated with circulating anti\u2013complement Factor H autoantibodies and complicated by cardiac and neurologic symptoms. Our observation highlights the efficacy of eculizumab in this form of aHUS not only on renal symptoms but also on the extrarenal symptoms. It also suggests that eculizumab should be used very promptly after aHUS presentation to prevent life-threatening complications and to reduce the risk of chronic disabilities. To obtain a complete inhibition of the effector limb activation, the advised dosage must be respected. After this initial therapy in the autoimmune aHUS form, a long-term immunosuppressive treatment should be considered, to prevent relapses by reducing anti\u2013complement Factor H autoantibody plasma levels.<\/jats:p>","DOI":"10.1542\/peds.2013-1594","type":"journal-article","created":{"date-parts":[[2014,5,20]],"date-time":"2014-05-20T03:56:05Z","timestamp":1400558165000},"page":"e1764-e1768","source":"Crossref","is-referenced-by-count":33,"title":["Eculizumab in Anti-Factor H Antibodies Associated With Atypical Hemolytic Uremic Syndrome"],"prefix":"10.1542","volume":"133","author":[{"given":"Benedetta","family":"Diamante Chiodini","sequence":"first","affiliation":[{"name":"Departments of Pediatric Nephrology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Davin","sequence":"additional","affiliation":[{"name":"Departments of Pediatric Nephrology, and"},{"name":"Department of Pediatric Nephrology, Emma Children\u2019s Hospital\u2013Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Corazza","sequence":"additional","affiliation":[{"name":"Department of Immunology, CHU Brugmann Hospital (ULB), Brussels, Belgium; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Khaldi","sequence":"additional","affiliation":[{"name":"Pediatric Cardiology, H\u00f4pital Universitaire des Enfants-Reine Fabiola, Universit\u00e9 Libre de Bruxelles (ULB), Brussels, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Dahan","sequence":"additional","affiliation":[{"name":"Center for Human Genetics, Universit\u00e9 Catholique de Louvain, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Ismaili","sequence":"additional","affiliation":[{"name":"Departments of Pediatric Nephrology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Adams","sequence":"additional","affiliation":[{"name":"Departments of Pediatric Nephrology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2014,6,1]]},"reference":[{"issue":"12","key":"2021121100560278000_B1","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1093\/ndt\/gfi166","article-title":"Complement and the kidney: what the nephrologist needs to know in 2006?","volume":"20","author":"Berger","year":"2005","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"2021121100560278000_B2","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","article-title":"Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.","volume":"108","author":"Caprioli","year":"2006","journal-title":"Blood"},{"issue":"8","key":"2021121100560278000_B3","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1681\/ASN.2006080811","article-title":"Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome.","volume":"18","author":"Sellier-Leclerc","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"2021121100560278000_B4","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2010030315","article-title":"Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome.","volume":"21","author":"Dragon-Durey","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2021121100560278000_B5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev.med.59.060106.185110","article-title":"Complement regulatory genes and hemolytic uremic syndromes.","volume":"59","author":"Kavanagh","year":"2008","journal-title":"Annu Rev Med"},{"issue":"11","key":"2021121100560278000_B6","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneph.2012.214","article-title":"Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.","volume":"8","author":"Zuber","year":"2012","journal-title":"Nat Rev Nephrol"},{"issue":"11","key":"2021121100560278000_B7","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrneph.2012.195","article-title":"STEC-HUS, atypical HUS and TTP are all diseases of complement activation.","volume":"8","author":"Noris","year":"2012","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"2021121100560278000_B8","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00467-013-2423-x","article-title":"Atypical HUS: time to take stock of current guidelines and outcome measures?","volume":"28","author":"Rees","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"2021121100560278000_B9","article-title":"Successful treatment of DEAP-HUS with eculizumab [published online ahead of print November 20, 2013].","author":"Noone","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"2021121100560278000_B10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1136\/adc.72.1.46","article-title":"Myocarditis and haemolytic uraemic syndrome.","volume":"72","author":"Abu-Arafeh","year":"1995","journal-title":"Arch Dis Child"},{"issue":"5","key":"2021121100560278000_B11","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2011-1685","article-title":"Preservation of renal function in atypical hemolytic uremic syndrome by eculizumab: a case report.","volume":"130","author":"Giordano","year":"2012","journal-title":"Pediatrics"},{"issue":"4","key":"2021121100560278000_B12","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00467-008-0964-1","article-title":"Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome.","volume":"24","author":"Ariceta","year":"2009","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"2021121100560278000_B13","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMc0809959","article-title":"Eculizumab for congenital atypical hemolytic-uremic syndrome.","volume":"360","author":"Gruppo","year":"2009","journal-title":"N Engl J Med"},{"issue":"4","key":"2021121100560278000_B14","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00467-010-1719-3","article-title":"Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome.","volume":"26","author":"Lapeyraque","year":"2011","journal-title":"Pediatr Nephrol"},{"issue":"8","key":"2021121100560278000_B15","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.2215\/CJN.01090209","article-title":"Complement inhibitor eculizumab in atypical hemolytic uremic syndrome.","volume":"4","author":"Mache","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"2021121100560278000_B16","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1055\/s-0030-1262885","article-title":"Anti-factor H autoantibody-associated hemolytic uremic syndrome: review of literature of the autoimmune form of HUS.","volume":"36","author":"Dragon-Durey","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"2021121100560278000_B17","article-title":"Cardiovascular complications in atypical haemolytic uraemic syndrome.","author":"Noris","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"2021121100560278000_B18","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1093\/ndt\/gfq160","article-title":"Myocardial infarction is a complication of factor H-associated atypical HUS.","volume":"25","author":"Sall\u00e9e","year":"2010","journal-title":"Nephrol Dial Transplant"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/133\/6\/e1764\/919861\/peds_2013-1594.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/133\/6\/e1764\/919861\/peds_2013-1594.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T08:25:31Z","timestamp":1639211131000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/133\/6\/e1764\/76069\/Eculizumab-in-Anti-Factor-H-Antibodies-Associated"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,1]]},"references-count":18,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,6,1]]},"published-print":{"date-parts":[[2014,6,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2013-1594","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,1]]}}}